Insular and hippocampal gray matter volume reductions in patients with major depressive disorder

PLoS One. 2014 Jul 22;9(7):e102692. doi: 10.1371/journal.pone.0102692. eCollection 2014.

Abstract

Background: Major depressive disorder is a serious psychiatric illness with a highly variable and heterogeneous clinical course. Due to the lack of consistent data from previous studies, the study of morphometric changes in major depressive disorder is still a major point of research requiring additional studies. The aim of the study presented here was to characterize and quantify regional gray matter abnormalities in a large sample of clinically well-characterized patients with major depressive disorder.

Methods: For this study one-hundred thirty two patients with major depressive disorder and 132 age- and gender-matched healthy control participants were included, 35 with their first episode and 97 with recurrent depression. To analyse gray matter abnormalities, voxel-based morphometry (VBM8) was employed on T1 weighted MRI data. We performed whole-brain analyses as well as a region-of-interest approach on the hippocampal formation, anterior cingulate cortex and amygdala, correlating the number of depressive episodes.

Results: Compared to healthy control persons, patients showed a strong gray-matter reduction in the right anterior insula. In addition, region-of-interest analyses revealed significant gray-matter reductions in the hippocampal formation. The observed alterations were more severe in patients with recurrent depressive episodes than in patients with a first episode. The number of depressive episodes was negatively correlated with gray-matter volume in the right hippocampus and right amygdala.

Conclusions: The anterior insula gray matter structure appears to be strongly affected in major depressive disorder and might play an important role in the neurobiology of depression. The hippocampal and amygdala volume loss cumulating with the number of episodes might be explained either by repeated neurotoxic stress or alternatively by higher relapse rates in patients showing hippocampal atrophy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Case-Control Studies
  • Depressive Disorder, Major / pathology*
  • Female
  • Gray Matter / pathology*
  • Hippocampus / pathology*
  • Humans
  • Male
  • Middle Aged
  • Organ Size
  • Young Adult

Grants and funding

The study was supported by grants of Innovative Medizinische Forschung (IMF) of the Medical Faculty of Münster (DA120309 to UD, DA111107 to UD, and DA211012 to UD) and Rolf-Dierichs-Stiftung (ZUW80037 to UD) to Udo Dannlowski. Furthermore this work was supported by a grant to Carsten Konrad by the Interdisciplinary Center for Clinical Research (IZKF FG4) of the University of Münster, Germany. Financial Disclosures: Prof. Volker Arolt, MD, PhD is member of advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Janssen-Organon, Eli Lilly, Lundbeck, Pfizer, Servier, and Wyeth. He also received grants from Astra-Zeneca, Lundbeck, and Wyeth. He chaired the committee for the "Wyeth Research Award Depression and Anxiety". Carsten Konrad has received a travel grant by Lundbeck. These co-operations have no relevance to the work covered in the manuscript. All other authors (Mirjam Stratmann, Harald Kugel, Axel Krug, Sonja Schöning, Patricia Ohrmann, Christina Uhlmann, Christian Postert, Thomas Suslow, Walter Heindel, Tilo Kircher, Udo Dannlowski) have no conflicts of interest to declare, financial or otherwise. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.